If you looked solely at its stock price, you might get the idea that Eli Lilly (NYSE: LLY) is having a bit of an off quarter.

Investors didn't like what they heard. The big pharma stock initially plunged close to 15% after the market opened on ...

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 830% — a ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 28.35% higher than today’s price of $802.49.

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.

Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY ... However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5 ...

The big pharma stock initially plunged close to 15% after the market opened on Thursday before bouncing back somewhat. Even with this partial rebound, Lilly's share price remains roughly 13% below ...